Monday, November 30, Pharmaceutical company Moderna applied to the Food and Drug Administration to authorize the vaccine for emergency use.
Moderna asked the FDA to review an expanded data set showing the vaccine is 94.1% effective at preventing COVID-19 and 100% effective at preventing severe cases of the disease.
The company said that if approved, injections for Americans could begin as early as December 21.
Moderna’s Chief Medical Officer Dr. Tal Zaks said he became emotional when he saw the data Saturday night.
“It was the first time I allowed myself to cry,” Dr. Zaks said. “We have a full expectation to change the course of this pandemic.”
The FDA will meet with its advisory committee in December to review Pfizer‘s and Moderna’s applications.